Biogen Deal Activity — 21 Deals Analyzed, 2018–2026

Twenty-one deals since July 2018 — that's Biogen's transaction ledger, and the trajectory tells a story that would have been unrecognizable five years ago. A company once synonymous with multiple sclerosis and neurology has executed a dramatic therapeutic pivot, deploying billions into immunology and ophthalmology while maintaining its neurological base. The $5.6B–$6B Apellis acquisition in 2026 is the capstone, but it's not an isolated event. It's the logical endpoint of a deliberate, multi-year repositioning that BD teams and biotech founders need to understand if they want Biogen's attention — and capital.

Biogen's Deal Portfolio

The pattern is unmistakable. Immunology dominates the recent deal mix — appearing in at least five of the ten most recent transactions — with ophthalmology elevated to a core franchise overnight via the Apellis deal. Neurology remains in the mix (orelabrutinib, ThecaFlex DRx), but it's no longer the center of gravity. Biogen is diversifying aggressively, and the data shows it's doing so by acquiring commercial-stage or late-stage assets rather than building from scratch. Rare disease, oncology, and women's health appear in the broader 21-deal dataset, but the recent velocity and capital concentration clearly favor immunology and ophthalmology.

This is not a company hedging its bets across a dozen therapeutic areas. Biogen is making concentrated wagers — the Apellis acquisition alone likely accounts for more than half the total deal value across all 21 transactions.

Deal Type Preferences

Biogen's preferred deal structures — acquisition, co-development, license, collaboration, and option — reveal a company that has shifted from exploration to conviction. The recent deal mix skews heavily toward outright acquisitions and exclusive licenses, with co-development and option deals appearing less frequently in the 2025–2026 window.

The average upfront ratio of 37.3% of total deal value (TDV) across the full 21-deal dataset sits right at the inflection point between buyer-friendly and seller-friendly. For context, typical biopharma licensing deals average 20–30% upfront for preclinical assets and 40–50% for Phase 3 or approved products. Biogen's 37.3% blended rate reflects a portfolio that leans toward later-stage, de-risked assets — particularly the approved products in the Apellis portfolio and the Phase 3 felzartamab and litifilimab deals.

What this means practically: Biogen is willing to pay meaningful upfront consideration when the clinical or commercial risk is materially reduced. They're not hunting for early-stage lottery tickets at a discount. The felzartamab deal — $100M upfront on an $850M TDV — represents an 11.8% upfront ratio, which is notably lean for a Phase 3 asset in immunology and suggests either significant milestone-heavy back-loading or favorable optionality for Biogen. Sellers should benchmark against this carefully using tools like the Deal Calculator.

The dominance of acquisitions in recent deal flow also signals something important about Biogen's current posture: they want control. Collaborations and options give flexibility, but they also give partners exit ramps and competing leverage. Biogen is buying companies and securing exclusive licenses, which tells you they're building franchises, not testing hypotheses.

Strategic Pattern

Three strategic threads run through Biogen's biogen deal activity over this period:

• Complement-driven immunology as the new core. The Apellis acquisition — encompassing pegcetacoplan, Syfovre, and Empaveli — is a $5.6B–$6B bet on complement biology. This isn't a pipeline play; Syfovre is approved and generating revenue in geographic atrophy. Biogen is buying a commercial franchise and the underlying platform. Felzartamab, an anti-CD38 antibody in Phase 3 for antibody-mediated rejection, extends the immunology thesis into transplant medicine. The undisclosed $1B TDV immunology deal from June 2026 adds further depth. Biogen is building a multi-asset immunology franchise with real urgency.
• Neurology maintained, not abandoned. Orelabrutinib (a BTK inhibitor with neuroimmunology applications) and ThecaFlex DRx keep Biogen active in neurology, but the capital allocation tells the truth: $85M for ThecaFlex vs. $6B for Apellis. Neurology deals are smaller, more targeted — filling specific gaps rather than defining the strategic direction. This is consistent with a company that still has Leqembi (lecanemab) and its MS franchise generating neurology revenue but no longer views neurology alone as a sufficient growth engine.
• Approved and Phase 3 assets preferred. Across the recent deals, the stage skew is overwhelmingly late. Syfovre is approved. Felzartamab is Phase 3. Litifilimab is Phase 3. The lone preclinical deal (the undisclosed immunology asset) is the exception, not the rule. Biogen's deal thesis is clear: pay up for de-risked assets, integrate them fast, and let the commercial infrastructure generate returns. This is a hallmark of a company under revenue pressure and shareholder scrutiny — they cannot afford five-year R&D timelines on in-licensed assets. They need pipeline additions that can impact revenue within 12–36 months. Check comparable late-stage deal benchmarks on our mega deal benchmarks page.

Biogen's 2026 deal velocity — six transactions in the first half of the year alone — signals a company executing against a board-level mandate to diversify revenue beyond neurology before competitive and patent pressures erode its base.

What This Means If You're Pitching to Biogen

If you're a biotech founder or BD lead considering Biogen as a partner or acquirer, here's what the data supports:

• Lead with immunology or ophthalmology. These are the TAs where Biogen is deploying the most capital and the fastest deal velocity. A complement biology asset, an anti-inflammatory mechanism with differentiated data in autoimmune indications, or a retinal disease program will get attention. Neurology isn't off the table, but the bar is higher — you need a differentiated mechanism (BTK inhibition, neuroimmunology crossover) rather than another me-too amyloid approach.
• Bring Phase 2 data or later. Biogen's recent deal pattern overwhelmingly favors clinical-stage assets. Preclinical deals happen, but the capital deployed is a fraction of what's available for Phase 3 or approved products. If you're preclinical, frame the conversation as an option or collaboration — don't pitch for an acquisition premium you won't get.
• Expect upfront pressure in licensing structures. The 37.3% average upfront ratio is respectable, but the felzartamab deal at 11.8% upfront shows Biogen will push for milestone-heavy structures when they have leverage. Come prepared with competitive process data or alternative term sheets. Use the Ambrosia Deal Calculator to benchmark where your asset should price relative to comparable transactions.
• Be open to full acquisition. Biogen's recent pattern favors outright acquisitions over partnerships. If you're a single-asset or platform company with a lead program in their target TAs, the most likely outcome is an acquisition conversation, not a co-development term sheet. Price accordingly — the Apellis deal shows Biogen will pay significant premiums for approved assets with commercial infrastructure.
• Anticipate speed. Six deals in H1 2026 means Biogen's BD team is operating at a cadence that requires fast diligence and decisive internal alignment. If your data room isn't ready and your board isn't aligned on valuation ranges, you'll lose the window. Biogen is moving fast, and they have alternatives.

Find Your Best Buyer Fit

Biogen is one of 850+ companies scored in our partner matching engine. If your asset sits in immunology, ophthalmology, or neurology — or if you're building a complement biology platform — run your profile through the calculator to see how Biogen stacks against other potential acquirers and licensing partners. The tool benchmarks upfront ratios, TDV ranges, and deal structure preferences against real transaction data, so you pitch with leverage, not guesswork.